FY2025 EPS Estimates for XOMA Royalty Lowered by Analyst

XOMA Royalty Corporation (NASDAQ:XOMA) – Research analysts at HC Wainwright cut their FY2025 earnings estimates for shares of XOMA Royalty in a note issued to investors on Thursday, December 11th. HC Wainwright analyst J. Pantginis now forecasts that the biotechnology company will post earnings of $0.51 per share for the year, down from their prior estimate of $1.17. HC Wainwright has a “Buy” rating and a $97.00 price objective on the stock. The consensus estimate for XOMA Royalty’s current full-year earnings is ($1.41) per share. HC Wainwright also issued estimates for XOMA Royalty’s Q4 2025 earnings at $0.05 EPS and FY2026 earnings at $0.61 EPS.

XOMA Royalty (NASDAQ:XOMA) last posted its quarterly earnings results on Wednesday, November 12th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.33). XOMA Royalty had a net margin of 32.28% and a return on equity of 2.91%. The company had revenue of $9.35 million during the quarter, compared to analyst estimates of $11.47 million.

Several other equities analysts have also issued reports on XOMA. UBS Group set a $76.00 target price on XOMA Royalty in a research report on Tuesday, December 9th. Wall Street Zen cut shares of XOMA Royalty from a “buy” rating to a “hold” rating in a report on Saturday, November 15th. Zacks Research downgraded shares of XOMA Royalty from a “hold” rating to a “strong sell” rating in a research note on Tuesday, November 18th. Leerink Partners reduced their price target on shares of XOMA Royalty from $58.00 to $45.00 and set an “outperform” rating on the stock in a research report on Thursday, December 11th. Finally, Stifel Nicolaus set a $50.00 price target on shares of XOMA Royalty in a report on Friday. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $60.60.

XOMA Royalty Trading Up 1.3%

NASDAQ XOMA opened at $25.83 on Monday. XOMA Royalty has a 12 month low of $18.35 and a 12 month high of $39.92. The stock has a 50-day simple moving average of $32.87 and a 200 day simple moving average of $31.07. The company has a current ratio of 3.91, a quick ratio of 3.91 and a debt-to-equity ratio of 1.07. The company has a market capitalization of $319.78 million, a PE ratio of 34.91 and a beta of 0.94.

Insider Buying and Selling

In other news, CFO Thomas M. Burns sold 4,330 shares of the company’s stock in a transaction that occurred on Monday, September 22nd. The shares were sold at an average price of $35.99, for a total value of $155,836.70. Following the completion of the transaction, the chief financial officer owned 30,079 shares in the company, valued at $1,082,543.21. This represents a 12.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Owen Hughes acquired 100,000 shares of the company’s stock in a transaction that occurred on Thursday, December 4th. The shares were bought at an average price of $25.05 per share, for a total transaction of $2,505,000.00. Following the completion of the acquisition, the chief executive officer owned 102,000 shares of the company’s stock, valued at $2,555,100. This trade represents a 5,000.00% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders own 7.20% of the company’s stock.

Institutional Trading of XOMA Royalty

Hedge funds and other institutional investors have recently modified their holdings of the company. Woodline Partners LP lifted its holdings in shares of XOMA Royalty by 16.5% in the third quarter. Woodline Partners LP now owns 209,945 shares of the biotechnology company’s stock valued at $8,091,000 after purchasing an additional 29,715 shares in the last quarter. Citadel Advisors LLC acquired a new stake in XOMA Royalty in the 3rd quarter valued at approximately $292,000. Man Group plc acquired a new stake in XOMA Royalty in the 3rd quarter valued at approximately $247,000. BNP Paribas Financial Markets lifted its stake in XOMA Royalty by 266.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,226 shares of the biotechnology company’s stock valued at $124,000 after acquiring an additional 2,346 shares in the last quarter. Finally, Russell Investments Group Ltd. boosted its position in XOMA Royalty by 3,436.4% during the 3rd quarter. Russell Investments Group Ltd. now owns 778 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 756 shares during the last quarter. Institutional investors and hedge funds own 95.92% of the company’s stock.

XOMA Royalty Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.